REMS That Block Generics Are ‘Major’ Problem For FDA, Jenkins Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Chief of new drugs office notes unintended consequence of safety legislation is thwarting development of ANDAs and biosimilars.
You may also be interested in...
US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry
US FDA’s recommendation against use of foreign-licensed reference products in clinical switching studies would result in procurement challenges and higher costs for biosimilar developers while also limiting where such studies could be conducted, some companies say.
US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry
US FDA’s recommendation against use of foreign-licensed reference products in clinical switching studies would result in procurement challenges and higher costs for biosimilar developers while also limiting where such studies could be conducted, some companies say.
REMS And Generics: GPhA Needs Legislation, Continues Education
GPhA says congressional action is only remedy after study estimates $5.4 billion in potential savings is lost annually because of brand manufacturers using REMS to prevent generic competition.